To the Editor We are hypertrophic cardiomyopathy (HCM) investigators with a major investment in strategies for the prevention of sudden death (SD) using implantable cardioverter-defibrillators (ICDs).1 In this regard, we read with interest the recent large multicenter European study from Norrish et al2 addressing risk stratification and selection of young patients with HCM for ICDs.
Maron BJ, Rowin EJ, Maron MS. Concerns About the HCM Risk-Kids Study. JAMA Cardiol. 2020;5(3):362–363. doi:10.1001/jamacardio.2019.5786
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: